Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2022 Aug 19;28(21):4634–4641. doi: 10.1158/1078-0432.CCR-22-1268

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

©2022 The Authors; Published by the American Association for Cancer Research

This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license.

PMC Copyright notice

Figure 3. Efficacy of CT900/Idetrexed in expansion cohorts of patients with ovarian cancer. A, Waterfall plot of patients with HGSOC treated on the expansion cohort. Percentage change from baseline in tumor size in the expansion cohort (n = 64*). *All patients with at least one complete follow-up scan, n = 63 shown on waterfall plot. B, Depth and duration of response of patients receiving 12 mg/m2/q2Wk based on α-FR expression — Efficacy of CT900/Idetrexed in expansion cohorts of patients with ovarian cancer. A, Waterfall plot of patients with high-grade serous ovarian cancer treated on the expansion cohort. Percentage change from baseline in tumor size in the expansion cohort (n = 64*). *All patients with at least one complete follow-up scan, n = 63 shown on waterfall plot. B, Depth and duration of response of patients receiving 12 mg/m²/q2Wk based on α-FR expression.